The Accelerating Medicines Partnership (AMP) is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies to transform the current model for developing new treatments by jointly identifying and validating promising biological targets of disease. Initially, the AMP program will focus on Alzheimer's disease, type 2 diabetes, and autoimmune disorders, specifically lupus and rheumatoid arthritis.
While technological advances have produced a wealth of data on the biological cause of disease, moving these discoveries into treatments has been far more difficult. Not all biological insights lead to effective drug targets, and choosing the wrong target can result in failures late in the drug development process, costing time, money, and ultimately, lives. The entire biomedical research community and the public have a shared interest in compressing the timelines, reducing the costs, and increasing the success rates of new targeted therapies.
The ultimate goal of the AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.
This Super Session will focus on the goals and implementation plans for the new AMP program and will also explore the evolution of large-scale public private partnerships in an evolving innovation ecosystem.
Sponsored by Eli Lilly and Company
Open to Education and Exhibition Access, Convention Access, Convention Access & Partnering
Session ID: 2587